Quick Facts

• Main Indication: Supports the management of major depressive disorder (MDD) in adults.
• Other Uses: May be used to manage panic disorder in certain regions.

---

Elopram (citalopram) is a prescription medication utilized in adults to support the management of certain mental health conditions. Its primary approved use is for the acute and ongoing treatment of major depressive disorder, often referred to as depression. This disorder is characterized by a prominent and persistent low mood that may interfere with daily functioning.

In addition to its main indication, the medication is also authorized in some countries for the management of panic disorder, a condition involving recurrent, unexpected panic attacks. For all uses, Elopram is intended to be part of a comprehensive therapeutic strategy as determined by a qualified healthcare provider. Individuals considering this treatment should review the official prescribing information for a complete regulatory overview and safety considerations. A full assessment of symptoms and medical history is necessary before treatment is initiated.

Who Can and Cannot Use Elopram (Citalopram)

Official regulatory documents establish clear eligibility requirements and restrictions for the use of Elopram (citalopram), primarily based on the patient's existing health conditions and age.

Contraindicated Populations (Must Not Use)

Citalopram is contraindicated (must not be used) in several specific patient groups:

• Patients with a known hypersensitivity (allergy) to citalopram or any ingredient in the product.
• Those currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping MAOI treatment. This restriction also applies to concomitant use with linezolid or intravenous methylene blue.
• Patients taking pimozide.
• Individuals with a congenital long QT syndrome or other known QT interval prolongation due to risk of serious heart rhythm abnormalities.

Restricted and Special Populations

• Pediatric Use: Citalopram is not approved for use in patients under 18 years of age.
• Geriatric Patients (typically ge 60 or ge 65 years): Use is allowed, but the maximum recommended daily dose is restricted to 20 mg.
• Hepatic Impairment and CYP2C19 Poor Metabolizers: For patients with reduced liver function or those classified as poor metabolizers of the drug, the maximum recommended daily dose is also restricted to 20 mg.

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for Escitalopram (Elopram) as stated in government-approved regulatory documents.

Contraindicated Combinations

Co-administration is formally prohibited with certain substances due to the risk of serious adverse reactions, including Serotonin Syndrome and QTc interval prolongation.

• Monoamine Oxidase Inhibitors (MAOIs): All MAOIs (including Moclobemide, Linezolid, and intravenous Methylene Blue) are contraindicated. A mandatory 14-day washout period is required when switching between Escitalopram and a psychiatric MAOI.
• Pimozide and other medicinal products known to prolong the QTc interval are prohibited.

Pharmacodynamic and Metabolic Interactions

Interactions are documented based on additive effects or metabolic changes.

Interaction Type	Interacting Substances (Examples)	Official Context/Restriction
Pharmacodynamic	Serotonergic Agents (e.g., Triptans, Tramadol, St. John’s Wort); Drugs Affecting Hemostasis (e.g., NSAIDs, Warfarin)	Increased risk of Serotonin Syndrome; Increased risk of Abnormal Bleeding
Pharmacokinetic	CYP2C19 Inhibitors (e.g., Omeprazole); CYP Inducers (e.g., Apalutamide)	May cause a moderate increase in Escitalopram plasma concentration; May decrease Escitalopram plasma concentration

Regulators advise avoiding alcohol consumption due to potential additive effects on concentration and alertness, though no formal pharmacokinetic interaction with food is documented.

Molecular Targeting: Selective Serotonin Reuptake Inhibition

Elopram's active molecule, Escitalopram, is a selective agent that acts by inhibiting the Serotonin Transporter (SERT) protein located on presynaptic neurons. This action physically blocks the removal of the neurotransmitter serotonin (5-HT) from the synaptic cleft, leading to an immediate increase in its concentration and prolonging its availability to engage postsynaptic receptors.

---

Pathway Modulation: Enhanced Serotonergic Tone and Neural Adaptation

The sustained elevation of 5-HT initiates a compensatory adaptive response in the brain's circuitry, which includes the gradual desensitization of 5-HT autoreceptors. This adaptive cascade is necessary for the transformation of the initial chemical surge into a sustained enhancement of serotonergic tone across various central nervous system (CNS) pathways. This modulation leads to changes in activity within neural circuits, particularly those that govern affective processing and related homeostatic regulation.

---

Physiological Effects and Mechanistic Limitations

The resulting physiological effect is a systemic adjustment of neurotransmission that alters the activity of brain regions involved in regulating stress and emotion. However, the mechanism's effectiveness is subject to biological variability linked to genetics (e.g., polymorphisms in the SERT gene), which may result in a constrained modulation of the serotonergic system in certain individuals, and the full effect profile requires the time necessary for cellular adaptation to occur.

How to Use Elopram: Official Administration Guidelines

Elopram (escitalopram) is administered exclusively via the oral route. It is available as film-coated tablets in strengths of 5 mg, 10 mg (scored), and 20 mg (scored), as well as an oral solution (1 mg per mL). This medicine is taken once daily and may be administered either in the morning or the evening, with or without food.

---

Standard Dosing and Schedule

Treatment for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in adults typically begins with an initial dose of 10 mg once daily. The standard adult dosing range is 10 to 20 mg daily, with 20 mg representing the maximum recommended daily dose. Dose adjustments are generally performed after a minimum interval of one week in adults.

---

Population-Specific Use

Specific dosage rules apply to certain populations to align with official labeling:

• Older Adults (Geriatric): The maximum recommended daily dose is limited to 10 mg once daily.
• Hepatic Impairment: Patients with reduced liver function are generally advised a maximum daily dose of 10 mg.

These modifications ensure adherence to the standardized protocol for these groups.

---

Administration Protocol

Patients using the oral solution must employ a marked measuring device to ensure accurate measurement of the prescribed dose. If a dose is missed, it should be skipped if it is closer to the time of the next scheduled dose; patients are instructed not to double the dose to compensate. Upon the decision to stop treatment, the official protocol advises that the medicine be discontinued via a gradual dose reduction (tapering) over time.

Research evidence / Overview of studies for Elopram

---

Evidence for Use in Major Depressive Disorder (MDD)

The evaluation of Elopram (Escitalopram) was studied for Major Depressive Disorder in a substantial number of research efforts. These efforts primarily consist of Randomized Controlled Trials (RCTs), which were used in research exploring how symptoms change over time. Many of these studies examined the medicine compared directly against a placebo or against other already-available antidepressant medicines.

These research designs focused on outcomes related to symptom intensity or variability. Studies reported measurements of remission rates (a return to a near symptom-free state) in the observed groups. Evidence derived from settings with varying symptom burdens indicates that observed patterns were reported across these short-term trials. While research exploring differences between Elopram and other similar medicines has sometimes yielded mixed findings, the clinical significance of small numerical differences observed between active drugs is debated in official regulatory reviews.

---

Evidence for Use in Panic Disorder

Elopram was evaluated in the context of Panic Disorder, a condition associated with acute or disruptive episodes. The available evidence primarily comes from short-term (10 to 12 weeks) double-blind, placebo-controlled RCTs. Research focused on outcomes describing episodic or acute changes, particularly the frequency of panic attacks and changes in the overall severity of panic symptoms. Studies measured and reported lower panic attack frequencies in the group receiving the medicine compared to the placebo group.

The evidence quality varies across studies when analyzing its place within the broader anxiety treatment landscape, and certainty remains low in the findings of some specific network meta-analyses. Also, the follow-up durations for controlled studies specific to relapse prevention in panic disorder were limited, leaving less extensive data for long-term outcomes.

---

Long-Term Evidence and Durability of Response

A key focus of research has been to examine the durability of response after the initial treatment phase. For Major Depressive Disorder, studies have explored the medicine's role in relapse prevention. These maintenance trials typically observed patient responses over periods of up to one year following a successful acute treatment phase. This research examined whether patients who initially responded could sustain the initial pattern of response over a longer duration. Long-term effects are not fully established, as there is limited information available from controlled trials that follow patients for multiple years.

---

The Research Landscape: Consistency and Gaps

The evidence base for Elopram includes multiple, generally consistent RCTs and systematic reviews conducted for the acute treatment of MDD. However, research contributes to understanding what is known and what is still uncertain. A notable limitation is that follow-up durations were limited in many controlled trials, particularly regarding long-term, multi-year outcomes. Comparative evidence is lacking for some direct head-to-head trials against newer therapeutic options.

How to Store and Dispose of Elopram

Elopram (Escitalopram) must be stored and disposed of according to specific regulatory requirements to maintain drug stability and safety.

---

Storage Requirements

Store the medication at controlled room temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF). The product must be protected from moisture and light and must be kept from freezing. Store Elopram in its original, tightly closed container. It is mandatory to keep the medicine out of the reach of children.

---

Disposal Instructions

The preferred method for disposing of unused or expired Elopram is to use an authorized drug take-back option. If a take-back program is unavailable, mix the medicine with an unappealing substance, place it in a sealed bag, and discard it in the household trash. The product must not be flushed down the toilet or poured into a drain.